Abstract
Our understanding of the determinants of human life span and longevity has increased markedly during the last few decades. A number of environmental, lifestyle and genetic factors associated with longevity have been identified, and the intricate interplay between these components has been recognized. Various therapeutic approaches, especially those at the somatotropic and immunological axes, have been presented as means to reverse some of the impairments that accompany the aging process. Nevertheless, a considerable level of unexplained interindividual variation exists in the human life span, and despite promising results in animal models, many of the rejuvenation trials in humans have yet to be successful. This review discusses the genetic component of human longevity and its phenotypic effectors: the biomarkers and their target pathways. The focus is set on the somatotropic and immunological axes. In addition, a new longevity biomarker candidate, a circulating cell-free DNA (cf-DNA), is presented. cf-DNA is unique in that virtually any dying or senescent cell type can release it, making it a sensitive and compelling biomarker for aging research. Lastly, this review discusses several of the rejuvenation strategies proposed to augment senescent phenotypes. Because there is a growing interest in personalized treatment modalities and risk prediction scores in various age-related disorders, we highlight some of the genetic and age- and sex-specific factors that can modulate the response to such interventions.
Keywords: Aging, longevity, biomarker, inflammation, caloric restriction, cf-DNA.
Current Pharmaceutical Design
Title:Determinants of Longevity: Genetics, Biomarkers and Therapeutic Approaches
Volume: 20 Issue: 38
Author(s): Juulia Jylhava
Affiliation:
Keywords: Aging, longevity, biomarker, inflammation, caloric restriction, cf-DNA.
Abstract: Our understanding of the determinants of human life span and longevity has increased markedly during the last few decades. A number of environmental, lifestyle and genetic factors associated with longevity have been identified, and the intricate interplay between these components has been recognized. Various therapeutic approaches, especially those at the somatotropic and immunological axes, have been presented as means to reverse some of the impairments that accompany the aging process. Nevertheless, a considerable level of unexplained interindividual variation exists in the human life span, and despite promising results in animal models, many of the rejuvenation trials in humans have yet to be successful. This review discusses the genetic component of human longevity and its phenotypic effectors: the biomarkers and their target pathways. The focus is set on the somatotropic and immunological axes. In addition, a new longevity biomarker candidate, a circulating cell-free DNA (cf-DNA), is presented. cf-DNA is unique in that virtually any dying or senescent cell type can release it, making it a sensitive and compelling biomarker for aging research. Lastly, this review discusses several of the rejuvenation strategies proposed to augment senescent phenotypes. Because there is a growing interest in personalized treatment modalities and risk prediction scores in various age-related disorders, we highlight some of the genetic and age- and sex-specific factors that can modulate the response to such interventions.
Export Options
About this article
Cite this article as:
Jylhava Juulia, Determinants of Longevity: Genetics, Biomarkers and Therapeutic Approaches, Current Pharmaceutical Design 2014; 20 (38) . https://dx.doi.org/10.2174/1381612820666140314153818
DOI https://dx.doi.org/10.2174/1381612820666140314153818 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy The Role of Infection in Carotid Plaque Pathogenesis and Stability: The Clinical Evidence
Current Vascular Pharmacology Endothelins Role in the Control of the Acute Phase of Trypanosoma cruzi Infection
Mini-Reviews in Medicinal Chemistry Nattokinase: An Updated Critical Review on Challenges and Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry SIRT1 – An Anti-Inflammatory Pathway at the Crossroads Between Metabolic Disease and Atherosclerosis
Current Vascular Pharmacology Treatment of Atherosclerotic Renovascular Disease
Current Hypertension Reviews Coronary Artery Disease and End-Stage Renal Disease - A Clinical Perspective
Current Hypertension Reviews Bioactive Compounds in Diabetic Cardiomyopathy: Current Approaches and Potential Diagnostic and Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Medicinal Plants and Atherosclerosis: A Review on Molecular Aspects
Current Pharmaceutical Design Progress in the Rational Design for Polypharmacology Drug
Current Pharmaceutical Design Subject Index To Volume 2
Current Women`s Health Reviews Update on the Molecular Genetic Studies of Behcets Disease
Current Rheumatology Reviews Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Biomarker Discovery and Translation in Metabolomics
Current Metabolomics The Relationship Between Inflammation, Platelet Activation and Antiplatelet Resistance
Inflammation & Allergy - Drug Targets (Discontinued) Regeneration of Pancreatic β-Cells in vivo as a Potential Therapeutic Approach for Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Arterial Stiffness as a Cardiovascular Risk Factor for the Development of Preeclampsia and Pharmacopreventive Options
Current Vascular Pharmacology An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
Current Drug Targets Prasugrel: A Novel Antiplatelet Therapy for Acute Coronary Syndromes
Recent Patents on Cardiovascular Drug Discovery Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets